Hosted on MSN1mon
Biogen’s higher dose Spinraza under review by US and EU regulators
Despite its early success, Spinraza faces increasing competition from newer SMA therapies. Roche’s Evrysdi (risdiplam), approved in the US in 2020 and the EU in 2021, is an oral treatment that ...
pharmaphorum9d
FDA cues up May verdict for Roche’s SMA challenger risdiplam
If approved, risdiplam will be the third drug to be approved for SMA after Biogen’s blockbuster antisense drug Spinraza (nusinersen) – which became the first drug to treat the muscle-wasting ...
pharmaphorum1mon
Novartis pulls rival to Roche’s risdiplam in SMA, says market limited
Both risdiplam and LMI070 are RNA-splicing drugs ... with the disease can also be treated with Biogen’s antisense drug Spinraza (nusinersen), given by injection into the spine, which became ...